Significantly, in comparison to a control group that received treatment solely with gefitinib, an EGFR inhibitor, the concurrent administration of Ad/ABE targeting SNPs in TP53 and EGFR, in conjunction with gefitinib, resulted in an enhanced drug sensitivity and a more effective suppression of abnormal tumor proliferation (Table 7). This evidence concerns the gene TP53 and neoplasm.